Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory
acute graft versus host disease (GVHD). PLX51107 is a novel, potent non-benzodiazepine
structured small molecule BET inhibitor with a unique binding mode selective for BRD4
inhibition and a more tolerable side effect profile. PLX51107 may work better in treating
steroid-refractory acute GVHD.